The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Final results of a phase II study of liposomal cisplatin -vinorelbine combination as first-line treatment in HER2/neu negative metastatic breast cancer.
F. S. Farhat
No relevant relationships to disclose
S. Temraz
No relevant relationships to disclose
J. G. Kattan
No relevant relationships to disclose
K. Ibrahim
No relevant relationships to disclose
N. Bitar
No relevant relationships to disclose
N. Haddad
No relevant relationships to disclose
H. Hatoum
No relevant relationships to disclose
A. Shamseddine
No relevant relationships to disclose